安杰思(688581)：海外业务稳健增长 投入加码赋能长期发展

Core Viewpoint - The company reported a revenue of 302 million yuan for the first half of 2025, reflecting a year-on-year increase of 14.56%, while the net profit attributable to shareholders was 126 million yuan, up by 1.26% year-on-year. However, the net profit after deducting non-recurring items decreased by 7.06% year-on-year, indicating some challenges in profitability despite revenue growth [1]. Group 1: Financial Performance - In Q2 2025, the company achieved a revenue of 174 million yuan, representing a year-on-year increase of 14.03%, while the net profit attributable to shareholders was 70 million yuan, down by 2.65% year-on-year [1]. - The company's overseas business showed strong growth, generating sales of 163 million yuan, up by 18.29% year-on-year, accounting for 53.8% of total revenue, an increase of 1.7 percentage points compared to H1 2024 [2]. - Domestic business also demonstrated resilience under procurement pressure, achieving revenue of 137 million yuan, a year-on-year increase of 10.07% [2]. Group 2: Strategic Developments - The company is enhancing its localization efforts to support overseas business development, with expectations of improved service capabilities as the Thailand factory begins operations and the U.S. subsidiary is completed [2]. - The company is investing in capacity expansion and new product development, leading to an increase in management and R&D expense ratios, which are 10.55% and 11.39% respectively [3]. - The company anticipates that the ongoing investment will contribute to long-term growth, with the endoscopy consumables industry currently experiencing high demand [3]. Group 3: Future Outlook - Revenue projections for 2025-2027 are estimated at 780 million, 974 million, and 1.214 billion yuan, with year-on-year growth rates of 22.5%, 24.9%, and 24.6% respectively [3]. - The expected net profit attributable to shareholders for the same period is projected to be 319 million, 383 million, and 474 million yuan, with respective growth rates of 8.6%, 20.2%, and 23.8% [3].